Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases
- The Digital LightCycler System is a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient’s cancer, genetic disease or infection.
- The new system has the potential to find and quantify ultra-rare, hard to detect mutations, leading to early diagnosis and treatment strategies.
- The Digital LightCycler System is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in areas such as oncology and infectious diseases.
Basel, 23 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Digital LightCyclerⓇ System, Roche’s first digital polymerase chain reaction ( PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods.
The Digital LightCycler System will allow clinical researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions. The system can then perform PCR and produce highly sophisticated data analysis on the results.
"Understanding the hidden characteristics of serious diseases is fundamental for ensuring that the most effective treatment is selected for each patient," said Thomas Schinecker, CEO of Roche Diagnostics. “The Digital LightCycler System will support clinical researchers and laboratories in identifying rare and emerging disease mutations. This can be instrumental in early diagnosis and therapy decisions."
For areas like oncology and infectious disease, the system provides new opportunities for researchers beyond what traditional PCR technology can achieve. This includes ultra rare targets, accurately quantifying how much of the target DNA or RNA there is at a molecular level, and other high precision analysis.
Roche has made significant contributions to establish and advance PCR technology over several decades. In 1991, Roche saw the potential in PCR and invested in refining the science for use in molecular diagnostics to detect pathogens and genetic code changes that lead to diseases.
The unique capabilities of the Digital LightCycler System complement the Roche suite of widely available PCR solutions. The launch of this new system adds to this PCR ecosystem, and builds on the company’s founding legacy in PCR. Both solutions will be offered by Roche, providing a suite of molecular solutions to the healthcare community.
The system will be available in 15 countries worldwide in 2022 with plans to launch into more countries in the near future. It will be CE-marked and has an FDA 510(k) exempt status.
About the Digital LightCyclerSystem
The Digital LightCycler System is the first digital PCR (dPCR) system from Roche and is intended for in-vitro diagnostic (IVD) testing. It performs absolute quantification of DNA and RNA targets using PCR technology. The Digital LightCycler System provides flexibility for laboratories through three unique reaction plates allowing customisation of the sample volumes used, the number of times a sample is partitioned (divided), and how many different tests can be run on a single sample (known as multiplexing). The system also features an easy workflow, moving from sample to results efficiently.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD Phone: +41 61 687 41 47 | Nathalie Altermatt Phone: +41 61 687 43 05 |
KarstenKleine Phone: +41 61 682 28 31 | Nina Mählitz Phone: +41 79 327 54 74 |
Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 | SileiaUrech Phone: +41 79 935 81 48 |
Roche Investor Relations Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com | Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Landsbankinn hf.: Correction: Covered bond offering results18.4.2024 12:30:10 CEST | Press release
Correction: Total amount issued following tap issuance corrected. Today, Landsbankinn concluded a covered bond auction where one series was offered for sale. A total of 15 bids for ISK 3,960m were received in the series LBANK CBI 30 at 3.56%-3.62% yield. Bids in the amount of ISK 3,580m were accepted in the series at 3.59% yield. Following the tap issuance, the total amount issued in the series will be ISK 14,640m. Settlement date will be 24 April 2024. Arion banki, Islandsbanki and Kvika act as market makers for covered bonds issued by Landsbankinn. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. The covered bonds are issued in accordance with a license from the Financial Supervisory Authority (FME), with reference to act. no. 11/2008 and FME‘s rules no. 190/2023. Further information on the bonds and the cover pool is available on Landsbankinn‘s website, Landsbankinn's funding - Landsbankinn.is.
Renewables and nascent low-carbon technologies most exposed to high interest rates18.4.2024 12:25:00 CEST | Press release
NEWS RELEASE Renewables and nascent low-carbon technologies most exposed to high interest rates Policymakers should focus on bolstering carbon markets, maximising subsidy efficiency and mobilising green finance LONDON, 18 April 2024 – If high interest rates persist, transitioning to a net zero global economy will be even harder and more costly. The higher cost of borrowing negatively affects renewables and nascent technologies, compared to more established oil and gas, and metals and mining sectors, which remain somewhat insulated, according to latest report: ‘Conflicts of interest: the cost of investing in the energy transition in a high interest-rate era’ by Wood Mackenzie. “Interest rates, which have risen sharply in the past two years, may not come down as far or as quickly as markets anticipate. This increased cost of capital has profound implications for the energy and natural resource industries, particularly the cost and pace of the transition to low-carbon technologies,” said
Storaktionærmeddelelse18.4.2024 12:01:52 CEST | pressemeddelelse
Selskabsmeddelelse nr. 18/2024 Holbæk, den 18. april 2024 Storaktionærmeddelelse Fonden for Sparekassen Sjælland har meddelt, at grundet Sparekassen Sjælland-Fyn A/S’s kapitalnedsættelse ejer fonden nu 5,08 % af aktiekapitalen i Sparekassen Sjælland-Fyn A/S. Med venlig hilsen Lars Petersson Jakob Andersson Adm. direktør Formand Yderligere information: Presse- og direktionsrådgiver Morten Huse Eikrem-Jeppesen, tlf. 53 85 07 70 Administrerende direktør Lars Petersson Sparekassedirektør Lars Bolding www.spks.dk/ir Vedhæftet fil Selskabsmeddelelse nr. 18 - 2024 - Storaktionærmeddelelse
CNH to release 2024 First Quarter financial results on May 218.4.2024 12:00:00 CEST | Press release
CNH to release 2024 First Quarter financial results on May 2 Basildon, April 18, 2024 CNH (NYSE: CNHI) will release its 2024 First Quarter financial results on Thursday, May 2, 2024. A live audio webcast of the financial results conference call will begin at 9:00 a.m. EDT (2:00 p.m. BST / 3:00 p.m. CEST) on the same day. It will be accessible at the following address: bit.ly/CNH_Q1_2024 For those unable to participate in the live session, a replay will remain archived in the Investor Relations section of the corporate website (www.cnh.com) for two weeks following the conference call. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breaking New Ground, which centers on Innovation, Sustainability and Productivity, the Company provides the strategic direction, R&D capabilities, and investments that enable the success of its global and regional Brands. Globally, Case IH and New Holland supply 360° agriculture applications from machines
Extraordinary General Meeting of Jyske Bank A/S held on 18 April 202418.4.2024 11:55:43 CEST | Press release
At the Extraordinary General Meeting of Jyske Bank held today, the motions set out in the agenda were finally adopted. The motions about amendments to the Articles of Association proposed by the Supervisory Board under items a.1 – a.4 of the agenda (concerning the remuneration structure for the Shareholders' Representatives, election of Supervisory Board members and handling of the salary and pension terms of the Executive Board) as well as the motion under item b of the agenda concerning the authorisation of the general meeting to the Supervisory Board for registration of the Articles of Association were all adopted. The Danish Business Authority is subsequently requested to register the adopted motions. Yours faithfully, Jyske Bank Contact person: CFO, Birger Krøgh Nielsen, phone +45 89 89 64 44. Attachment EGM_20240418